A Review on Nanoparticles for the Treatment in Parkinson's Disease

Abstract

Parkinson's disease is the second most common progressive neurodegenerative disease that promotes neuronal cell death. The primary treatment strategy for Parkinson's disease involves the therapy of an MAO-B inhibitor molecule. Nanotechnology refers to the creation and utilization of materials whose constituents exist at the nanoscale; and, by convention, be up to 100 nm in size. Nanotechnology explores electrical, optical, and magnetic activity as well as structural behavior at the molecular and submolecular level. It has the potential to revolutionize a series of medical and biotechnology tools and procedures so that they are portable, cheaper, safer, and easier to administer. Nanoparticles show very high mechanical properties as well as many remarkable physical properties. Their reactivity, durability and different properties are additionally reliant upon their novel size, shape and construction; there is appropriate possibility for different business and homegrown applications, which incorporate catalysis, imaging, clinical applications, energy-based examination, and ecological applications. Alzheimer's disease (AD) is a neurodegenerative disorder for which the research of new treatments is highly challenging. Since the fibrillogenesis of amyloid-β peptide 1–42 (Aβ_1–42) peptide is considered as a major cause of neuronal degeneration, specific interest has been focused on aromatic molecules for targeting this peptide.